Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Monday that it has received US Food and Drug Administration (FDA) approval for Gazyva (obinutuzumab) to treat adults with primary membranous nephropathy (pMN) at risk of disease progression, making it the first and only approved treatment for the condition.
The approval is based on Phase III MAJESTY trial results, which showed that 36.1% of patients receiving Gazyva achieved complete remission of proteinuria after two years, compared with 5.7% for tacrolimus. Overall remission rates were 50% and 12.9%, respectively, with no new safety signals identified.
Primary membranous nephropathy is a rare, chronic autoimmune disease that can cause irreversible kidney damage and progress to kidney failure.
This approval marks Gazyva's third FDA authorisation in immune-mediated kidney diseases, following previous approvals for idiopathic nephrotic syndrome and lupus nephritis. The FDA is also reviewing Gazyva for systemic lupus erythematosus, with a decision expected by December 2026, while a European regulatory decision is anticipated following a positive recommendation from the CHMP.
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
Agilent acquires Proscia for USD240m
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m